As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory materials of Tetrapeptide 21 from multiple well-known brands.
As a R&D-oriented foreign trade service provider, HiSiaddi is not limited to self-promotion like single-brand manufacturers. We objectively analyze multiple top market-share brands in China and worldwide, and share their major technological progress and breakthroughs to provide buyers with authentic, up-to-date market insights.
If you require more comprehensive and valuable market information about Tetrapeptide 21, please contact HiSiaddi customer service.
1. Vichytech: Solved high loss pain points of traditional solid-phase peptide synthesis through mass production of Tetrapeptide 21 via enzyme-catalyzed segmented splicing technology. Crude product conversion rate increased from 68% to 92.7%; finished HPLC purity upgraded from 98.2% to 99.5% with single impurity ≤0.05%, crossing the impurity threshold set by European and American pharmacopoeias. Mass export to EU and North American raw material suppliers commenced in Q1 2026.
2. Sino Peptide: Leveraged AI molecular simulation screening + one-step traceless cyclization auxiliary modification technology to optimize terminal amino modification of Tetrapeptide 21. Without altering the core GEKG (Gly-Glu-Lys-Gly) sequence, water solubility increased by 37% to eliminate low-temperature liquid precipitation and enable direct feeding for aqueous essence formulations without pre-treatment. Procurement Benefits: Raw material purchase price reduced by 18% year-on-year; no additional refining required, higher feeding tolerance for downstream skincare factories and reduced formulation rework losses.
Sumei Raw Materials: Patented short side-chain cyclic modification targeting the lysine site of Tetrapeptide 21 addresses the vulnerability of stock solutions to enzymatic hydrolysis and activity loss under ambient conditions. Unmodified material retains only 72% activity after 6 months at room temperature, while modified material maintains ≥93% activity after 24 months without cold-chain transportation, removing temperature control restrictions for long-distance cross-border shipping of Tetrapeptide 21. Procurement Benefits: Overseas warehousing and cross-border cold-chain logistics costs reduced by 32%; small-batch stocking becomes feasible for small and mid-sized end brands, lowering raw material inventory losses.
Shandong Blue Ocean Peptide Industry: Matched self-developed elastin peptide EDP sustained-release hydrogel carriers to achieve 72-hour long-acting sustained release of Tetrapeptide 21. Free Tetrapeptide 21 delivers instantaneous skin transdermal penetration of 26.6%, while carrier-bound material achieves controlled sustained release with 2.3x higher retention in the dermal layer, overcoming the bottleneck of superficial loss after topical application of conventional raw materials. Guangzhou Qianxiang Bio: Finalized targeted compounding process for Tetrapeptide 21 + Pentapeptide-18; the compound raw material boosts collagen synthesis efficiency by 41% compared to standalone Tetrapeptide 21. It has passed EU CosIng new ingredient filing and is exclusively supplied to OEM manufacturers of European and American salon repair skincare products. End-product Benefits: Equivalent anti-wrinkle and firming efficacy at identical formulation addition rates, enabling brands to lower formulation dosage, reduce production costs and retain room for end-product pricing adjustments.
Sederma (France, Global Market Share No.1): Newly commissioned genetically engineered bacterial fermentation production line in 2026 produces Tetrapeptide 21 intracellularly via engineered E. coli, eliminating chemical amino acid condensation routes. Carbon emissions reduced by 55% and per-ton production energy consumption cut by 42%. Natural origin labeling complies with EU Clean Beauty regulations for natural ingredient claims. Procurement Benefits: Meets labeling requirements for European and American clean beauty, enabling buyers to classify end products as natural skincare and expand access to supermarket and cosmeceutical channels.
Lipotec (Spain): New product with site-specific phosphorylation modification at the glutamate residue of Tetrapeptide 21 delivers 58% higher skin fibronectin production than standard Tetrapeptide 21. Formulated for barrier-damaged and mature sagging skin, it has been exclusively supplied to customized raw material lines of Estée Lauder and SkinCeuticals high-end collections since 2026. End-product Benefits: Enhanced efficacy for sensitive skin and post-procedure repair lines, supporting differentiated barrier repair product portfolios and increased premium pricing potential for end brands.
Merck (Germany): Self-developed 0.08μm phospholipid nanosphere encapsulation technology stabilizes Tetrapeptide 21 in oil-based systems, breaking the original limitation of exclusive water solubility that restricted application to creams and oil balms. This expands use cases to oil-based skincare and body lotions. Procurement Benefits: A single raw material adapts to full-spectrum aqueous and oil-based formulations, reducing raw material inventory categories and streamlining supply chains for buyers.
Mitsubishi Chemical: Optimized multi-stage nanofiltration concentration and purification process lowers the minimum formulation effective dosage of high-activity Tetrapeptide 21 from 0.2% to 0.06%, drastically cutting formulation cost occupancy and enabling mass-market drugstore skincare formulations. End-product Benefits: Affordable mass-market skincare brands can incorporate high-end anti-aging tetrapeptides at low cost, bringing premium anti-aging ingredients to mass consumer lines and boosting end-product cost performance.
Lipo (USA): Upgraded aseptic vacuum lyophilization production lines produce medical-grade Tetrapeptide 21 lyophilized powder with total microbial count <10CFU/g, meeting FDA raw material standards for medical dressings. New application avenues include medical cold compresses and microneedle dressing raw materials. Procurement Benefits: Buyers can expand downstream business to cover both cosmetic and medical aesthetics markets, broadening product application channels.
1.
For Raw Material Buyers (Traders & Skincare OEM Manufacturers) ① Cost: Combined raw material unit price, logistics and formulation processing costs reduced by 15%–33% ② Compliance: Modified and biosynthetic materials align with the latest cosmetic regulations of EU, US and Japan, lowering customs filing risks ③ Product Portfolio: Single raw material compatible with aqueous, oil-based and medical dressing formulations, streamlining raw material procurement lists
2.
3.
For End Skincare Brands & Consumers ① Efficacy: Significantly enhanced firming, collagen-boosting and barrier repair effects at identical formulation costs ② Pricing: High-end lines deliver upgraded efficacy for higher premiums; mass-market lines incorporate premium tetrapeptides at low cost to reduce end retail prices ③ Safety: Modified materials feature reduced irritation, expanding suitable user groups including sensitive skin and post-procedure skin
4.
If you require more comprehensive and valuable market information about Tetrapeptide 21, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
